[HTML] nih.gov

[HTML][HTML] CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed …

…, JE Cortes, LF Newell, TL Lin, EK Ritchie… - Journal of Clinical …, 2018 - ncbi.nlm.nih.gov
Purpose CPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin
that delivers a synergistic 5: 1 drug ratio into leukemia cells to a greater extent than normal …
Save Cite Cited by 892 Related articles All 22 versions
[HTML] nih.gov

Somatic mutations precede acute myeloid leukemia years before diagnosis

…, MS Simon, G Cheang, S Lee, M Samuel, EK Ritchie… - Nature medicine, 2018 - nature.com
The pattern of somatic mutations observed at diagnosis of acute myeloid leukemia (AML) has
been well-characterized. However, the premalignant mutational landscape of AML and its …
Save Cite Cited by 561 Related articles All 7 versions
[PDF] unimi.it

Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia …

…, AK Fielding, A Rambaldi, EK Ritchie… - Journal of Clinical …, 2017 - air.unimi.it
Purpose Few therapeutic options are available for patients with Philadelphia chromosome-positive
(Ph (+)) B-precursor acute lymphoblastic leukemia (ALL) who progress after failure of …
Save Cite Cited by 387 Related articles All 11 versions View as HTML
[HTML] nih.gov

[HTML][HTML] First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5: 1 molar ratio for the treatment of relapsed and …

…, JE Lancet, JE Kolitz, EK Ritchie… - Journal of Clinical …, 2011 - ncbi.nlm.nih.gov
… Ritchie, Gail J. Roboz, Alan F. List, Steven L. … Ritchie, Gail J. Roboz, Alan F. List,
Steven L. … Ritchie, Gail J. Roboz, Alan F. List, Steven L. …
Save Cite Cited by 334 Related articles All 10 versions

CPX-351 versus 7+ 3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results …

…, GL Uy, LF Newell, TL Lin, EK Ritchie… - The Lancet …, 2021 - thelancet.com
Background Daunorubicin and cytarabine are used as standard induction chemotherapy for
patients with acute myeloid leukaemia. CPX-351 is a dual-drug liposomal encapsulation of …
Save Cite Cited by 119 Related articles All 8 versions

Final results of a phase III randomized trial of CPX-351 versus 7+ 3 in older patients with newly diagnosed high risk (secondary) AML.

…, GL Uy, JE Cortes, LF Newell, TL Lin, EK Ritchie… - 2016 - ascopubs.org
7000 Background: Older patients with secondary AML have poor outcomes following first-line
cytarabine and anthracycline-based treatment. CPX-351 is a liposomal formulation of …
Save Cite Cited by 223 Related articles
[HTML] nih.gov

[HTML][HTML] Addition of navitoclax to ongoing ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: phase II safety and efficacy

…, C Jamieson, R Mesa, EK Ritchie… - Journal of Clinical …, 2022 - ncbi.nlm.nih.gov
PURPOSE Targeting the BCL-X L pathway has demonstrated the ability to overcome Janus
kinase inhibitor resistance in preclinical models. This phase II trial investigated the efficacy …
Save Cite Cited by 78 Related articles All 10 versions
[HTML] nih.gov

Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia

EK Ritchie, EJ Feldman, PJ Christos… - Leukemia & …, 2013 - Taylor & Francis
Abstract Treatment options for older patients with acute myeloid leukemia (AML) and for
patients with relapsed/refractory AML are limited, and outcomes are poor. Decitabine, a …
Save Cite Cited by 197 Related articles All 6 versions
[HTML] nih.gov

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled …

F Ravandi, EK Ritchie, H Sayar, JE Lancet… - The lancet …, 2015 - thelancet.com
Background Safe and effective treatments are urgently needed for patients with relapsed or
refractory acute myeloid leukaemia. We investigated the efficacy and safety of vosaroxin, a …
Save Cite Cited by 180 Related articles All 18 versions
[HTML] sciencedirect.com

Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML

…, CM Ippoliti, TJ Curcio, EK Ritchie… - Blood, The Journal …, 2011 - ashpublications.org
We conducted an open-label phase 1 study exploring the feasibility, safety, and biologic
activity of epigenetic priming with decitabine before standard induction chemotherapy in …
Save Cite Cited by 175 Related articles All 14 versions